The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials
Open accessAbstract
The insulin-like growth factor-I receptor (IGF-IR) was first cloned in 1986. Since then, intense work has defined classic phosphorelays activated via the IGF-IR, which regulate cell proliferation, apoptosis, motility, and fate. The understanding of the roles of hormones in cancer and the growth hormone–IGF–IGF-binding protein axis specifically has yield to a second wave of development: the design of specific inhibitors that interrupt the signaling associated with this axis. The ability to manipulate these pathways holds not only significant therapeutic implications but also increase the chance of deeper insight about the role of the axis in carcinogenesis and metastasis. Nowadays, >25 molecules with the same goal are at different stages of development. Here, we review the clinical and preclinical experience with the two most-investigated strategies, tyrosine kinase inhibitors and monoclonal antibodies, and the advantages and disadvantages of each strategy, as well as other alternatives and possible drug combinations. We also review the biomarkers explored in the first clinical trials, the strategies that have been explored thus far, and the clinical trials that are going to explore their role in cancer treatment. [Mol Cancer Ther 2008;7(9):2575–88]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Nahta, R., Yuan, L. X. H., Du, Y., & Esteva, F. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0423 · Cited by 267
PPARγ as a therapeutic target for tumor angiogenesis and metastasis
Panigraphy, D., Huang, S., Kieran, M. W., & Kaipainen, A. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.7.2014 · Cited by 137
Cited by
The role of androgens and estrogens on healthy aging and longevity
Horstman, A. M., Dillon, E. L., Urban, R. J., & Sheffield-Moore, M. (2012) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/gls068 · Cited by 396
Mulvihill, M. J., Cooke, A., Rosenfeld-Franklin, M., Buck, E., Foreman, K., Landfair, D., O’Connor, M., Pirritt, C., Sun, Y., Yao, Y., et al. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.89 · Cited by 311
Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies
Brahmkhatri, V. P., Prasanna, C., & Atreya, H. S. (2015) · BioMed Research International · doi:10.1155/2015/538019 · Cited by 279
Gualberto, A., & Pollak, M. (2009) · Oncogene · doi:10.1038/onc.2009.172 · Cited by 274
Metadata
- Authors
- Rodon, J., DeSantos, V., Ferry, R. J., & Kurzrock, R.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2008-09-01
- Volume
- 7
- Issue
- 9
- Pages
- 2575-2588
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2133403258
- Cited by
- 162
- References
- 3
- FWCI
- 20.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. https://app.cochat.ai/papers/10.1158/1535-7163.mct-08-0265
- The paper
- Rodon, J., DeSantos, V., Ferry, R. J., & Kurzrock, R. (2008). Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-08-0265
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.